• Dr. Bobby Gaspar On Manufacturing, Commercialization Challenges

    Orchard Therapeutics CEO Dr. Bobby Gaspar, M.D., Ph.D. is one of only a handful of gene therapy leaders to see the light of market-approved therapy. Here, he offers advice for those seeing manufacturing, regulatory, and reimbursement challenges for the first time.

$2,000-Per-Dose Cell Therapy In The Clinic

With its ongoing Phase 1 clinical trial of ACE1702 for the treatment of HER2-expressing solid tumors, Acepodia founder, CEO, and president, Sonny Hsiao, Ph.D. and SVP of R&D, Mark Gilbert, M.D., make a case for fast, affordable, and effective off-the-shelf cell therapies.

Beating The AAV Vector Immunogenicity Challenge

In many gene therapy applications, an immune response barrier stands in the way of leveraging adeno-associated virus vectors. Here’s how Dr. Carsten Brunn’s clinical-stage firm Selecta Biosciences is addressing the challenge with its nanoparticle technology-based platform.

Renewed Innovation In Vaccine Development

As scientific and investment interests in vaccine development advances crescendo on the back of COVID-19, Cincinnati-based biotech startup Blue Water Vaccines seeks to revolutionize the approach to influenza vaccinations. We caught up with CEO Joseph Hernandez for the story.

Beating Stem Cell Sourcing, Exosome Production Challenges

Urgent medical needs like COVID-19 therapeutics are fueling new interest in cell-based therapies, despite a years-long, uphill social battle. Here’s how one company’s persistent, global pursuit of safely harvested biologics is positioning it to address the greatest medical need of our time. 


  • Important cGMP Considerations For Implementing Electronic Batch Records

    Mistakes in batch records can have considerable consequences for the release of medicines in terms of delays and rejections. Errors can be minimized through the implementation of electronic batch records. However, with any electronic system within the pharmaceutical industry, the requirements of current good manufacturing practice (cGMP), including those of data integrity, need to be met. 

  • Incorporating Excipients Into QbD Studies For Drug Development — An Introduction

    This article is the first in a three-part series based on information from the new guide Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design, published by the International Pharmaceutical Excipients Council Federation. Topics covered include measuring the impact of excipient variability on finished product quality and more!

  • FDA Steps Up Support For Advanced Manufacturing Technologies

    In its latest move to encourage the broader adoption of advanced manufacturing technologies, the FDA has entered into a memorandum of understanding (MOU) with the National Institute of Standards and Technology (NIST) that combines the strength of FDA’s regulatory expertise and NIST’s globally recognized precision characterization and standards. The MOU is significant because it takes the next step in providing much-needed guidance and resources to the industry.

  • FDA’s COVID-19 PREPP Initiative Summary Report — Key Takeaways For Manufacturers

    Published in January 2021, the FDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative Summary Report is the culmination of work performed by the FDA’s PREPP Initiative, which launched in April 2020 to examine lessons learned from the agency’s response to the global COVID-19 pandemic. This article provides a brief overview of the report’s overarching themes and highlights key regulatory insights for manufacturers in light of two action areas in particular.

  • Developing Future Delivery Models For ATMPs: Practical Considerations

    With a small number of approved cell therapies/ex-vivo gene therapies, and with those approved therapies reaching small patient populations, there is not a proven strategy to answer the questions about large-scale commercial manufacturing. The developers of these processes are taking different strategies for commercial manufacturing as they weigh several factors.

  • 7 Rules For Properly Interpreting Control Charts

    It is time to consider augmenting your validated production processes, including processing, packaging, and labeling, with continuous process monitoring using control charts to ensure continued compliance with established specifications and requirements. 

  • 9 Rules For Cleaning Verification & Validation Of Multipurpose API Plants

    Cleaning validation continues to be a hot topic during regulatory inspections and industry discussions. The cleaning required in an active pharmaceutical ingredient (API) plant between one manufacturing process and the next can present a huge challenge, particularly when multipurpose plants are used.

  • Do These Recent Drug GMP Warning Letters Signal A Shift In FDA Enforcement Focus?

    The FDA posted two unique warning letters that all pharmaceutical and API firms, regardless of their product category, should consider and evaluate. These first-of-a-kind warning letters represent a renewed emphasis on both alternatives to on-site inspections and the importance of purchasing controls and supplier management.





As the initiative to combat the global pandemic continues to play out and consume supply chain resources, the fast-approaching requirements of the Drug Supply Chain Security Act (DSCSA) remain. To help biopharma supply chain pros juggle these equally high priorities, we've assembled a collection of columns on these supply chain considerations, authored by independent experts on the topics at hand. We trust you'll find their guidance valuable.

More Content Collections